DELFI Diagnostics
Baltimore, MD · Biotechnology · 171 employees
DELFI Diagnostics is developing next-generation blood-based cancer detection tests designed to be accurate, accessible, and scalable for population health. Its technology is based on fragmentomics, using machine learning to analyze patterns in cell-free DNA from a simple blood draw. DELFI’s first test, FirstLook Lung, supports lung cancer screening by reliably identifying individuals who may have
Funding history
- Funding Round — $34.3M — Dec 2025
- Funding Round — $225.0M — Jul 2022
- Series series b — $225.0M — Jul 2022
- Funding Round — $101.1M — Jan 2021
- Funding Round — $5.5M — Aug 2019
Recent signals
- Jan 08, 2026: DELFI Diagnostics Appoints Cindy Soriano as Chief Financial Officer
- Dec 18, 2025: Raised $34.3M
- Dec 02, 2024: DELFI Diagnostics Appoints Dr. Amoolya Singh as Chief Technology Officer
- Jan 05, 2024: DELFI Diagnostics Appoints Susan Tousi as New Chief Executive Officer
- Jun 01, 2023: DELFI Diagnostics Hires David Morgenstern, PhD, as Vice President of Clinical Development
- Jul 25, 2022: Raised $225.0M
- Jul 18, 2022: Raised $225.0M in Series series b
- Jan 27, 2021: Raised $101.1M
See plans & pricing → Track DELFI Diagnostics’s funding, hiring, and signals — with verified contacts — on Fundz.